However, the tumor microenvironment (TME) of NSCLC is affected by a variety of driver oncogenes (drivers) and exhibits significant heterogeneity, which leads to different sensitivities of patients to treatment with immune checkpoint inhibitors (ICIs) for PD‐L1/PD‐1 [18]. The gene discussed is CD274; the disease is neoplasm.